Valneva SE (NAS:VALN)
$ 4.3307 0.1342 (3.2%) Market Cap: 351.65 Mil Enterprise Value: 398.38 Mil PE Ratio: 0 PB Ratio: 1.60 GF Score: 69/100

Q1 2021 Valneva SE Earnings Call Transcript

May 20, 2021 / 01:00PM GMT
Release Date Price: $30.31 (-0.17%)
Operator

Good day, and thank you for standing by. Welcome to the Valneva Reports Q1 2021 Financial Results and Business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your first speaker today, Mr. Thomas Lingelbach. Please go ahead. .

Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Very good day. Welcome to our quarter 1 results and business update call. So yes, so the quarter 1, 2021 has been marked by excellent progress on our clinical programs. We have been able to initiate an additional Phase II study on Lyme to accelerate the pediatric development within our partnership with Pfizer. We transitioned our COVID vaccine candidate into Phase III and started the Phase III trial for the vaccine against COVID-19, and we completed the enrollment of our chikungunya Phase III study. So all 3 assets where we will -- where we are either the only in class, best-in-class or first-in-class, and we are very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot